期刊
JOURNAL OF VIRAL HEPATITIS
卷 18, 期 5, 页码 331-337出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1365-2893.2010.01310.x
关键词
cholesterol; HMG CoA reductase; lipoprotein; lipoviroparticle; statin
资金
- Schering Plough Research Institute, Kenilworth, NJ, USA
- SPRI
- AASLD Sheila Sherlock Clinical and Translational Research Award in Liver Diseases
- Gastroenterology Society of Australia
- NIH [T32 HL079896]
HMG CoA reductase inhibition suppresses in vitro HCV replication through depletion of cellular sterol proteins such as geranylgeraniol. Our aims were to prospectively evaluate the changes in serum and lipid fraction HCV RNA with Rosuvastatin in non-responder (NR) patients with CHC. A total of 11 patients with CHC genotype-1 received Rosuvastatin at 20 mg qd (weeks 0-4), 40 mg qd (weeks 5-12), with 4 week follow up. Lipid fractions were separated by a sucrose density gradient ultracentrifugation, HCV RNA determined at wks 0, 2, 4, 8, 12, 16 in serum, and in selected very low- (VLDF) to high-density (HDF) lipid fractions. A reduction in LDL and total cholesterol (TC) was not accompanied by significant decline in HCV RNA. At baseline, there was an inverse correlation between HDL and HCV RNA (rho = -0.45, P = 0.036). At 20 mg, there was correlation between change (Delta) in TG and Delta HCV RNA (rho = 0.75, P = 0.007), Delta ALT and Delta TC (rho = -0.64, P = 0.03) and Delta LDL (rho = -0.67, P = 0.02). At 40 mg, Delta TG maintained a positive correlation with Delta HCV RNA (rho = 0.65, P = 0.03). There was a group difference for HCV RNA in relation to lipid fractions (P = 0.04) but not study time intervals (P = 0.17); mean log HCV RNA was greater in VLDF compared to HDF (5.81 +/- 0.59 vs 5.06 +/- 0.67, P = 0.0002) with no other differences to study time intervals (P = 0.099). Short-term Rosuvastatin monotherapy is not associated with significant changes in serum or lipid fraction HCV RNA in NR patients. HCV co-localizes with the lowest density lipid fractions in serum.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据